Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 2/20 | 0.42 |
| ▸ | MMP9 | P14780 | 2/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 8/20 | 0.41 |
| ▸ | PDCD1 | Q15116 | 6/20 | 0.41 |
| ▸ | PYGL | P06737 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | FNTA | P49354 | 1/20 | 0.39 |
| ▸ | FNTB | P49356 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2249746 | 0.89 | KDM4E (0.48) | L3MBTL1KMT2AMMP2MMP9PYGL | |
| SCHEMBL2250693 | 0.84 | HPGDS (0.42) | MMP2CD274PDCD1KDM4CCA1 | |
| SCHEMBL10889781 | 0.82 | PDCD1 (0.44) | L3MBTL1CD274PDCD1KDM4CFNTA | |
| SCHEMBL29213421 | 0.82 | PDCD1 (0.41) | L3MBTL1CD274PDCD1PYGLKDM4C | |
| SCHEMBL29213425 | 0.82 | PDCD1 (0.41) | L3MBTL1CD274PDCD1PYGLKDM4C | |
| SCHEMBL12389068 | 0.80 | KMT2A (0.49) | L3MBTL1KMT2AMMP2MMP9CA2 | |
| SCHEMBL8545079 | 0.79 | L3MBTL1 (0.56) | L3MBTL1KMT2AMMP2MMP9CD274 | |
| SCHEMBL2245801 | 0.79 | FOLH1 (0.53) | KMT2AMMP2MMP9FNTAFNTB | |
| SCHEMBL2252963 | 0.78 | FOLH1 (0.51) | KMT2AMMP2MMP9CA2CA1 | |
| SCHEMBL13402410 | 0.78 | KDM4E (0.45) | L3MBTL1KMT2AMMP2MMP9CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998965-B2 | Glutamate aggrecanase inhibitors | WYETH LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | WYETH (US) | 2010-01-14 | — | — | US | disclosed |
| US-7553873-B2 | Glutamate aggrecanase inhibitors | WYETH (US) | 2009-06-30 | — | — | US | disclosed |
| EP-1902014-A2 | GLUTAMATE AGGRECANASE INHIBITORS | Wyeth (US) | 2008-03-26 | — | — | EP | disclosed |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | WYETH (US) | 2007-02-22 | — | — | US | disclosed |
| WO-2007008994-A2 | GLUTAMATE AGGRECANASE INHIBITORS | WYETH (US) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | ADAMTS5, ADAMTS1, ADAMTS7 | L3MBTL1 4308/4885KMT2A 2364/4885MMP2 49/4885 |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | ADAMTS5, ADAMTS1, ADAMTS7 | L3MBTL1 4308/4885KMT2A 2364/4885MMP2 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.